· ISIN: US17322U2078

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

CRANFORD, N.J., Feb. 14, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal first quarter ended December 31, 2024. Fi...

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

This news feed is a compilation of company-relevant news from the most popular and widest-reaching newswire services. The feed is updated several times. For market-related publications, we recommend the X-Billboard, the Daily News Digest or our Premium Information Service.
Most recent update: 14.02.2025 | 22:30
14 February 2025 10:30PM
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
CRANFORD, N.J., Feb. 14, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal first quarter ended December 31, 2024. Fi...
© PR Newswire
06 February 2025 02:55PM
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services
Permanent J-Code (J9161) expected to be effective April 1, 2025 LYMPHIR is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. CRANFORD, N.J., Feb. 6, 2025 /PRNewswire/ -- Citius Pharmaceutica...
© PR Newswire
08 January 2025 02:00PM
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
CRANFORD, N.J., Jan. 8, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into definitive agreements for the purchase of an aggregate of 743,...
© PR Newswire
07 January 2025 02:08PM
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025
CRANFORD, N.J., Jan. 7, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius Oncology (Nasdaq: CTOR), today announced significant progress in preparations for the commercial launch of LYMPHIR™, an innovative immunotherapy for the treatment of adults with re...
© PR Newswire
06 January 2025 01:50PM
Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives
CRANFORD, N.J., Jan. 6, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or "the Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that it has retained Jefferies LLC as its exclusive financial advisor to assist in evaluating strategic alternatives a...
© PR Newswire
27 December 2024 11:00PM
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update
Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J., Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and f...
© PR Newswire
25 November 2024 02:03PM
Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval
CRANFORD, N.J., Nov. 25, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that the Company held a constructive in-person Type C meeting with the U.S. Food and...
© PR Newswire
22 November 2024 03:00PM
Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split
CRANFORD, N.J., Nov. 22, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) announced today that it will be executing a reverse stock split of its common stock, par value $0.001 per share, at a ratio of 1-for-25 ("Reverse Stock Split"). Pursuant to the laws of the State of Nevada and subject to pri...
© PR Newswire
18 November 2024 10:05PM
Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering
CRANFORD, N.J., Nov. 18, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today closed its previously announced registered direct offering for the purchase of an aggregate of 1...
© PR Newswire
15 November 2024 07:30PM
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering
CRANFORD, N.J., Nov. 15, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into definitive agreements for the purchase of an aggregate of 12,...
© PR Newswire
11 November 2024 02:45PM
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors
Study, in patients with solid tumors focusing on gynecological malignant tumors such as ovarian, endometrial, and cervical, nearing completion with three remaining subjects to be enrolled 27% Objective Response Rate (ORR) 33% Clinical Benefit Rate (CBR) with a median Progression Free Survival (PFS) of 57 weeks Chemotherapy-free immunomodulatory r...
© PR Newswire
05 September 2024 10:30PM
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
CEO Leonard Mazur to present on Tuesday, September 10, 2024, at 9:00 am ET CRANFORD, N.J., Sept. 5, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), today announced that Chairman and CEO Leonard Mazur will present and host one-on-one investor meetings at the H.C. Wainwright & Co. 26th Annual...
© PR Newswire
05 September 2024 02:30PM
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
CRANFORD, N.J., Sept. 5, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), today announced that LYMPHIR™ has been added to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). LYMPHIR is included based on an NCCN Catego...
© PR Newswire
12 August 2024 11:28PM
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update
Granted FDA approval of LYMPHIR™ for the treatment of cutaneous T-cell lymphoma Completed merger of oncology subsidiary with TenX Keane; Citius Oncology expected to begin trading on Nasdaq on August 13, 2024, under ticker CTOR Achieved primary and secondary endpoints of Mino-Lok® Phase 3 Trial CRANFORD, N.J., Aug. 12, 2024 /PRNewswire/ -- Citius...
© PR Newswire
12 August 2024 10:22PM
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.
LYMPHIR™ for the treatment of cutaneous T-cell lymphoma approved by the FDA Citius Pharmaceuticals, Inc. holds approximately 90% of publicly traded Citius Oncology, Inc. Shares of Citius Oncology, Inc. anticipated to begin trading on Nasdaq under the ticker "CTOR" on August 13, 2024 CRANFORD, N.J., Aug. 12, 2024 /PRNewswire/ -- Citius Pharmaceut...
© PR Newswire
12 August 2024 02:00PM
Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments
Management call scheduled for Tuesday, August 13, 2024, at 8:30 AM ET CRANFORD, N.J., Aug. 12, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), today announced that it will host an investor call on Tuesday, August 13, 2024 at 8:30 am ET to discuss recent and upcoming developments. Citius Chairma...
© PR Newswire
08 August 2024 12:59PM
Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
Only systemic treatment for relapsed or refractory (r/r) CTCL to target the IL-2 receptor on malignant T-cells and TregsLYMPHIR is expected to launch within the next five monthsLYMPHIR's approval marks the first novel targeted systemic therapy approved by the FDA r/r CTCL since 2018Approval based on Phase 3 Pivotal Study 302 results that demonstr...
© PR Newswire
27 January 2020 02:00PM
Biotech Companies Think Big with Specialization - Fighting Deadly Bacteria and Viruses
Point Roberts, Washington and Vancouver, British Columbia--(Newsfile Corp. - January 27, 2020) - Investorideas.com, a leading investor news resource covering pharmaceutical and biotechnology stocks releases a special report on the opportunity within the specialty drug segment of the sector to address viral outbreaks and bacterial resistance, featur...

The information service offers company-relevant news from leading newswire services in a compact form for a quick overview. When the detailed view is called up, further information can be accessed if required. The navigation elements in previewer mode allow you to quickly switch to the most frequently visited tool sections. From there, you can access further areas that can be used for your own research and analysis. Tip: The information platform now includes more than 50 mini-apps developed in-house.

AI First: Feel free to test the AI integration that will quickly put you on a par with financial journalists and research houses

Further information

The information presented in this section is secondary publications. The content corresponds to the source information. You can find information on the author of the news item in the detailed information of a publication. News relating to listed companies may have been created due to regulatory publication obligations, due to regular public relations work for PR or marketing reasons or by third parties against the background of investor information.

The combination of information and graphic elements contributes significantly to visual orientation and navigation through complex issues. This makes it easier to grasp, contextualize and process key content. Images, logos and other or comparable graphic and textual elements used on the information portal are used for visual navigation, are part of the original message or have illustrative purposes. All rights to these elements are held by the respective owners of the trademark or image rights. They are used without intent to infringe copyright or intellectual property rights. Image material provided via the distribution networks is treated as part of the original message and processed accordingly.

If you believe that copyright or intellectual property rights have been infringed by the presentation, please contact us immediately to clarify your concerns.